Tuesday, November 25, 2014 10:35:27 PM
Based on recent PR they hired agency that will do work of uplisting before Oct'15. I have feeling that once Lympro is commercialized they will have enough cash on hand + Royalty payments and based on cash position they should be able to uplist and attract more investors that will help advance new drugs in the pipeline.
I'm not in favor of uplisting or spin-off because in both cases you get fractional shares and if you invested because you like specific product of company, you will get fractional shares after spinoff.
It all depends on how much they will get from Lympro and how much money they will need to advance ESS and Eltoprazine. Both have ODD so it might be cheaper. But If I have enough cash to advance them then I would not do uplisting or spinoff. There are lot of companies trading > $1 in OTC so I don't think it will affect SP because fundamental valuation of company doesn't change regardless of which exchange it is trading.
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM